CeriBell (NASDAQ:CBLL) Stock: Insider Raymond Woo Sells 4,887 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.38, for a total transaction of $119,145.06. Following the transaction, the chief technology officer owned 203,118 shares in the company, valued at $4,952,016.84. The trade was a 2.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Raymond Woo also recently made the following trade(s):

• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.33, for a total transaction of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Trading Up 0.3%

NASDAQ:CBLL traded up $0.08 during trading hours on Friday, hitting $23.69. 305,317 shares of the stock were exchanged, compared to its average volume of 344,626. The company has a market capitalization of $909.17 million, a P/E ratio of -13.46 and a beta of 0.94. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $22.64 and its two-hundred day moving average is $20.21. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.63.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC bought a new stake in shares of CeriBell in the 2nd quarter valued at about $638,000. Wellington Management Group LLP raised its position in shares of CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. bought a new position in CeriBell during the 2nd quarter worth approximately $603,000. Bank of America Corp DE acquired a new position in CeriBell during the second quarter valued at approximately $4,619,000. Finally, PDT Partners LLC bought a new stake in CeriBell in the second quarter valued at approximately $1,026,000.

Wall Street Analyst Weigh In

CBLL has been the subject of a number of research reports. TD Cowen lifted their price objective on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group raised their target price on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a research note on Friday, September 11th. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.00.

CeriBell Company Profile

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.